Resumen

DE ABREU, Maximiliano  y  TAJER, Carlos D.. Dual Antiplatelet Therapy Under Scrutiny: Real Benefit and Risk Subgroups. Rev. argent. cardiol. [online]. 2013, vol.81, n.5, pp.427-434. ISSN 1850-3748.

CURE, TRITON-TIMI 38 and PLATO studies have demonstrated clinical benefit with the use of dual antiplatelet therapy with clopidogrel, prasugrel or ticagrelor in addition to aspirin in patients with acute coronary syndrome, and have contributed to exponentially increased prescription. The publication of new randomized trials with findings contrasting with the benefits obtained in these studies and of some opinion articles which have questioned the validity of the results, make it necessary, at least, to rethink the general indication and actual clinical benefit of these drugs. In this article we discuss the results of these three trials as well as the methodological objections that have been posed to them, focusing on the real clinical benefit of these drugs. Likewise, the probability of prejudice in certain subgroups is discussed and a simple scheme that allows the selection of patients most likely to benefit from these treatments is postulated.

Palabras clave : Antiplatelets; p2y12 Receptor Antagonist; Acute Coronary Syndromes.